Bill curbs private equity in health care

Summary#

SB 666, titled the “Keep Wall Street Out of Health Care Act,” would create a new New Hampshire law on certain health care transactions and establish a legislative study committee. Its stated goal is to protect consumers from harmful consolidation and changes to cost, access, or care quality; that is a goal, not a guaranteed result. The bill was referred to interim study and is not law.

  • Health care transaction parties would have to notify the Department of Justice at least 60 days before closing if a transaction meets the bill’s definition of “material.”
  • The Department would review these transactions and could prohibit one or impose conditions, including limits on service cuts, staffing, debt, or payments to owners.
  • The bill would require disclosures about ownership, investors, debt, planned payments to owners, and expected effects on competition, costs, access, staffing, and clinical services.
  • Private equity entities, for-profit owners, and management services organizations could not interfere with licensed professionals’ clinical judgment, subject to stated exceptions for administrative oversight and other practices.
  • A five-member legislative committee would study private health insurers and report findings and recommendations. It would not be a new insurance regulator.

What it means for you#

  • Patients and consumers: The bill would let the Department act against covered transactions it finds likely to harm competition, care quality, access, or cost. It does not guarantee lower prices, continued services, or a particular care outcome.
  • Health care providers and transaction parties: Hospitals, clinics, physician practices, and other entities licensed or certified to provide care could be covered. Parties to a covered transaction would have to provide the required notice and detailed disclosures. The bill’s definition includes changes of control and some affiliations; it also specifically covers material transactions involving private equity or for-profit entities.
  • Health care professionals: The bill would bar private equity entities, for-profit owners, and management services organizations from directing clinical judgment. A professional harmed by a violation could seek a court order to stop it; the bill does not give that person a private right to seek damages under this provision.
  • Legislators: The committee would have three senators and two representatives. Members would receive mileage for committee work, and the committee would have to report by November 30, 2026.
  • Taxpayers: The Department would take on transaction reviews, monitoring, enforcement, and annual reporting. The bill does not fund or authorize new positions.

Money#

The fiscal note estimates an annual state cost of $100,000 to $500,000 in FY 2028 and FY 2029; the exact cost is indeterminable.

  • The Department estimates needing three positions, with combined costs of about $362,000 in FY 2028 and $374,000 in FY 2029.
  • The bill provides no funding and does not authorize those positions. The study committee would also receive mileage, with no cost estimate provided.
  • The fiscal note estimates no state revenue change.

What is unclear#

  • “Material” effect is not given a numerical threshold, and the bill does not explain how the Department would decide which transactions qualify.
  • The bill sets a 30-day review period but does not specify what happens if the Department needs more time, or whether a transaction may close while review or enforcement is ongoing.
  • It does not set a penalty amount or give detailed rules for transaction filings, hearings, appeals, or ongoing monitoring.
  • The bill does not explain how its requirements would interact with existing state or federal review processes. The supplied material does not include current RSA 358-A or other relevant law, so existing protections and remedies cannot be verified.
  • The health insurance committee’s study scope is broad, but the bill gives it no specific access to insurer records or other investigative powers.

Case for#

  • A possible argument for the bill is that ownership changes can affect competition, prices, access, and care, so state review before certain transactions close could help identify risks.
  • Required disclosures about investors, debt, and payments to owners could give the Department information to assess those risks.
  • The Department could impose conditions or prohibit a transaction rather than relying only on action after harm occurs.
  • The clinical-judgment rule could help protect patient care from financial directions by owners or management companies.

Case against#

  • The bill sets a 30-day review deadline across a broad range of transactions, but does not spell out filing procedures or what happens when review is incomplete. This could leave parties uncertain about timing and requirements.
  • The Department could impose wide-ranging conditions or seek to undo a completed transaction, while the bill does not set detailed standards or processes for those decisions.
  • The bill requires new review and enforcement work but provides no funding or authority for the positions the Department says it needs.
  • Key terms such as “materially affect” are not precisely defined, leaving uncertainty about which transactions and management decisions would be covered.